Sepsis & infection

Suppression of microbial burden to reduce pneumonia in critical illness: the SMURF feasibility pilot study

Crit CarePublished Prospective non-randomised feasibility pilot study

Authors' conclusion

Implementation of nasal aPDT in the ICU was feasible and safe, with high sampling adherence and successful blinded adjudication.

Study context

Population
Adults ≥ 19 years with expected ICU stay > 48 h, mixed medical-surgical ICUs, tertiary academic hospitalanalysed
Participants
227 adults
Comparison
Intervention vs Control
  • Interventionn = 101
  • Controln = 126reference
Primary endpoint
Feasibility: recruitment rate, protocol adherence, safety, data completeness, and ability to adjudicate pneumonia events (blinded, rule-based, CDC/NHSN definitions)
Methodological detailssingle-centre, sequential control and intervention phases
  • Single-centre
  • Sequential control and intervention phases

Primary result

As reported in the abstract

Feasibility

Adherence to scheduled nasal swab collection

97.7%

Scheduled antimicrobial photodynamic therapy (aPDT) treatments delivered in full (intervention phase)

57.8%

Scheduled aPDT treatments partially delivered (intervention phase)

12.0%

Further findings

OutcomeInterventionControlIRR (95% CI)
Adjudicated VAP/HAP incidence (exploratory)Exploratory analysis9.0 per 1,000 ICU patient-days14.9 per 1,000 ICU patient-days0.61 (0.31–1.17)
OutcomeP value
Early cumulative nasal pathogen burden (exploratory)Significantly lower in the intervention group · exploratory analysisP < 0.01

Hierarchical composite endpoint (pneumonia, microbiologic clearance, cumulative pathogen burden)

Win ratio favoring treatment
1.29 (95% CI 0.74-2.31)
  • Exploratory analysis

Safety

Intervention-related serious adverse events
0 · events

Original publication

Suppression of microbial burden to reduce pneumonia in critical illness: the SMURF feasibility pilot study. Crit Care. Published 7 April 2026. doi:10.1186/s13054-026-06008-7

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.